Mayo Clinic Laboratories > Therapeutics > Precision therapeutics > Precision mental and behavioral health therapeutics

Precision mental and behavioral health therapeutics

Empowering clinicians with data-driven insights

Psychiatric and neurologic treatments have historically relied on a trial-and-error approach, leading to prolonged treatment adjustments, adverse effects, and inconsistent outcomes. With more than 200 neuropsychiatric drugs available, individual variability in drug response remains a critical challenge.

58

As of March 2020, the U.S. FDA has included PGx biomarker information in 58 drug labels across psychiatry (n=34) and neurology (n=24) therapeutic areas1

154

154 neuropsychiatric drugs have listed therapeutic reference intervals2

>200

Over the past 60 years, more than 200 drugs have been discovered and developed for the treatment of psychiatric and neurologic patients2

Testing services

Mood disorders Mood disorders
Mood disorders 

OurPharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression. 

Precision pain management Precision pain management
Precision pain management

Precision pain management is among the most common legitimate uses for controlled substance therapy. Our streamlined approach to controlled substance monitoring ensures accurate results through validity testing and interpretive reports.

Mayo Clinic Laboratories’ Precision Mental and Behavioral Health Therapeutics initiative leverages cutting-edge diagnostic solutions to optimize medication management for psychiatric and neurologic patients. By integrating therapeutic drug monitoring (TDM), pharmacogenomics (PGx), and compliance monitoring, we provide a comprehensive approach to personalizing treatment, enhancing safety, and improving therapeutic outcomes.

Our advanced testing portfolio empowers clinicians with data-driven insights to:

  • Optimize drug dosing through real-time serum level monitoring.
  • Personalize medication selection based on genetic factors.
  • Ensure adherence and mitigate risks of controlled and addictive substances.

By delivering precise, patient-centered solutions, we help healthcare providers enhance treatment efficacy, reduce adverse effects, and drive better mental and behavioral health outcomes.

Resources
Learn more The Mayo Clinic Department of Psychiatry and Psychology
Learn more Diagnosing and treating more than 500 neurological conditions
Learn more The Psychiatric Genomics and Pharmacogenomics Program
References
  1. Pharmacogenetic Testing in Psychiatry and Neurology: an Overview of Reviews https://www.tandfonline.com/doi/full/10.2217/pgs-2020-0187
  2. Consensus Guidelines for Therapeutic Drug Monitoring in  Neuropsychopharmacology: Update 2017 s-0043-116492.pdf
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.